OR WAIT null SECS
The investment in the company’s Mississauga, Canada, laboratory includes an expansion of existing cell/tissue culture capabilities, flow cytometry, mass spectrometry facilities, and more.
SGS, a bio/pharmaceutical, analytical and bioanalytical contract solutions provider, announced on Oct. 23, 2018 that it is adding new in vitro toxicology services at its Mississauga, Canada laboratory.
The investment includes an expansion of existing cell/tissue culture capabilities, flow cytometry and mass spectrometry facilities, along with the introduction of high throughput screening, automation, and multiplexing technologies such as the Meso Sector S 600 for biomarker analysis.
The company’s investment in instruments and expansion of the laboratory's capabilities will allow clients to establish the toxicological profiles of bio/pharmaceuticals, medical devices, cosmetics, and chemicals. The new suite of services covers over 50 analytical techniques, including dermal and ocular toxicity, cytotoxicity, genotoxicity, carcinogenicity, phototoxicity, endocrine disruption, hepatotoxicity, and cardiotoxicity. The new service offerings will be available under both R&D and good laboratory practice (Organization for Economic Co-operation and Development, FDA Part 58) study conditions.
"Recent technical advancements and new government regulations have led to the rapid development of new, cost effective testing for the establishment of drug, device, chemical, and cosmetic safety," said Dr. Alex Perieteanu, director of Biopharmaceutical Services at SGS Canada, in a company press release. "SGS is an organization with a strong global reputation for quality and integrity, and this investment aligns the laboratory with the three Rs-the principles of replacement, reduction, and refinement-for more humane experimental research, and ensures patient safety and accelerating product development."